Download
1 / 5
50 likes | 61 Views
This study investigates the association between BCL6 exon-1 mutation and DLBCL subgroups, BCL6 protein/mRNA expression, and overall survival in DLBCL patients with different IPI scores.
E N D
Supplemental Figure 1 ABC GCB PM UNC
Supplemental Figure 2 (B) (A) DLBCL subgroups DLBCL subgroups BCL6 exon-1 mutation ABC GCB PM - + - + - + ABC GCB PM - + - + - + BCL6 protein expression (%positive cells) BCL6 mRNA expression (log 2) n= 42 1 41 9 11 1 32 0 36 7 8 1 p-value= 0.34 0.40 indicates mutations affecting BCL6 binding sites in exon-1
Supplemental Figure 3 Median expression + - Exon-1 BCL6 mutation status No of cases 9 14 BCL6 mRNA ATR IP-10 ISGF3 MIP-1a STAT1 9-27 (IFITM1) I-8U (IFITM3) EBI2 CD80 P27kip1 CD44 P21* BCLXL ID2 STAT3 CD69 IL18 P53 CXCR4 NF-kB1 Blimp-1 Consistent BCL6 target genes Less consistent *indirect target relative mRNA expression
Supplemental Figure 4 (A) (B) High IPI patients p=0.06 High IPI patients p=0.005 BCL6 mRNA lower half (n=36) upper half (n=36) BCL6 protein Negative(<30%, n=18 ) Positive (>30%, n= 21) Overall survival Overall survival Years Years
Supplemental Figure 5 (A) (B) Low IPI patients p=0.02 All DLBCL patients p<0.001 BCL6 mutation status Wild type (n=27) Mutant (n=45) BCL6 mutation status Wild type (n=50) Mutant (n=76) Overall survival Overall survival Years Years (C) High IPI patients p=0.008 BCL6 mutation status Wild type (n=17) Mutant (n=19) Overall survival Years
